Additional quality and supply challenges impacting Getinge’s earnings in Q2 and FY 2023
Getinge expects a negative impact of approximately SEK 400 M on EBITA in Q2 2023. The main reasons are additional quality and supply challenges in May-June within Acute Care Therapies’ two product categories Cardiopulmonary and Cardiac Assist. The company foresees a negative impact on sales, mix and earnings for the rest of the year.Getinge has previously informed about potential breaches in sterile packaging of consumables for ECMO therapy (HLS- and PLS-sets) within the product category Cardiopulmonary. In May 2023, Getinge notified customers globally about a voluntary medical device